Meeting
2022 ASCO Annual Meeting
Genomic correlates of response to capecitabine and temozolomide (CAPTEM) in pancreatic neuroendocrine tumors.
Authors
Patrick Lee
Cedars-Sinai Medical Center, Los Angeles, CA
Patrick Lee , Edik Matthew Blais , Jun Gong , Arsen Osipov , Natalie Moshayedi , Shant Thomassian , Camille Ng , Jennifer W. Chuy , Lynn McCormick Matrisian , Emanuel Petricoin III, Michael J. Pishvaian , Andrew Eugene Hendifar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Neuroendocrine/Carcinoid
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 4124)
DOI
10.1200/JCO.2022.40.16_suppl.4124
Abstract #
4124
Poster Bd #
110
Abstract Disclosures
Similar Posters
Poster
2016 Gastrointestinal Cancers Symposium
Next-generation sequencing (NGS) in advanced well differentiated pancreatic neuroendocrine tumors (WD pNETs): A study using MSK-IMPACT.
First Author: Nitya Prabhakar Raj
Poster
2018 Gastrointestinal Cancers Symposium
Utility of comprehensive genomic profiling (CGP) to distinguish neoplasms pathologically diagnosed as PanNETs and PanNECs and identify potentially actionable genomic alterations (GA).
First Author: Aatur D. Singhi
Poster
2019 Gastrointestinal Cancers Symposium
Multiplatform profiling of pancreatic neuroendocrine tumors (PanNETs) identifies novel co-occurring pathogenic alterations and associations with clinicopathologic factors.
First Author: Michelle Guan
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Next-generation sequencing (NGS) of circulating cell-free DNA (cfDNA) in advanced pancreatic neuroendocrine neoplasms (PanNENs).
First Author: Darren Cowzer